Patricia E. Noker

3.0k total citations · 1 hit paper
28 papers, 2.4k citations indexed

About

Patricia E. Noker is a scholar working on Molecular Biology, Oncology and Environmental Chemistry. According to data from OpenAlex, Patricia E. Noker has authored 28 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Environmental Chemistry. Recurrent topics in Patricia E. Noker's work include Per- and polyfluoroalkyl substances research (6 papers), Virus-based gene therapy research (5 papers) and Toxic Organic Pollutants Impact (4 papers). Patricia E. Noker is often cited by papers focused on Per- and polyfluoroalkyl substances research (6 papers), Virus-based gene therapy research (5 papers) and Toxic Organic Pollutants Impact (4 papers). Patricia E. Noker collaborates with scholars based in United States, Sweden and Malaysia. Patricia E. Noker's co-authors include Gregory S. Gorman, Shu‐Ching Chang, David J. Ehresman, John L. Butenhoff, Lee Jia, Andrew Yang, Leslie Louie, Donald J. Dykes, Zhiwen Yao and Joseph E. Tomaszewski and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Patricia E. Noker

26 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

2006 901 citations Patricia E. Noker et al. profile →

Peers

Countries citing papers authored by Patricia E. Noker

Since Specialization

Citations

This map shows the geographic impact of Patricia E. Noker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia E. Noker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia E. Noker more than expected).

Fields of papers citing papers by Patricia E. Noker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia E. Noker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia E. Noker. The network helps show where Patricia E. Noker may publish in the future.

Co-authorship network of co-authors of Patricia E. Noker

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia E. Noker. A scholar is included among the top collaborators of Patricia E. Noker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia E. Noker. Patricia E. Noker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates 2014 ·Justin C. Roth, Kevin A. Cassady, James J. Cody, (unknown), Kathleen H. Price, Jennifer Coleman, James O. Peggins, Patricia E. Noker, (unknown), Sheila Grimes, Steven L. Carroll, G. Yancey Gillespie, Richard J. Whitley, James M. Markert	3
2	Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates 2014 ·PubMed ·Justin C. Roth, Kevin A. Cassady, James J. Cody, (unknown), Kathleen H. Price, Jennifer Coleman, James O. Peggins, Patricia E. Noker, (unknown), Sheila Grimes, Steven L. Carroll, G. Yancey Gillespie, Richard J. Whitley, James M. Markert	60
3	Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate 2012 ·Toxicology ·Clifford R. Elcombe, Barbara M. Elcombe, John R. Foster, Shu‐Ching Chang, David J. Ehresman, Patricia E. Noker, John L. Butenhoff	26
4	P24—Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys 2012 ·Reproductive Toxicology ·Shu‐Ching Chang, David J. Ehresman, Patricia E. Noker, Gregory S. Gorman, Jill A. Hart, (unknown), (unknown), (unknown), John L. Butenhoff	1
5	Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys 2011 ·Reproductive Toxicology ·Maria Sundström, Shu‐Ching Chang, Patricia E. Noker, Gregory S. Gorman, Jill A. Hart, David J. Ehresman, Åke Bergman, John L. Butenhoff	148
6	Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys 2011 ·Reproductive Toxicology ·Shu‐Ching Chang, Patricia E. Noker, Gregory S. Gorman, Sheila J. Gibson, Jill A. Hart, David J. Ehresman, John L. Butenhoff	141
7	Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination 2010 ·Cancer Chemotherapy and Pharmacology ·Lee Jia, Gregory S. Gorman, Lori Coward, Patricia E. Noker, David L. McCormick, Thomas Horn, (unknown), Miguel Muzzio, Bellur S. Prabhakar, Balaji Ganesh, Tapas K. Das Gupta, Craig W. Beattie	56
8	A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans 2008 ·Toxicology ·Geary W. Olsen, Shu‐Ching Chang, Patricia E. Noker, Gregory S. Gorman, David J. Ehresman, Paul H. Lieder, John L. Butenhoff	285
9	Pharmacokinetics and pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate 2008 ·Journal of Pharmacy and Pharmacology ·Lee Jia, Patricia E. Noker, Gary A. Piazza, Carola Leuschner, William Hansel, Gregory S. Gorman, Lori Coward, Joseph E. Tomaszewski	11
10	Comparative Pharmacokinetics of Perfluorobutyrate in Rats, Mice, Monkeys, and Humans and Relevance to Human Exposure via Drinking Water 2008 ·Toxicological Sciences ·Shu‐Ching Chang, Kaberi Das, David J. Ehresman, Mark Ellefson, Gregory S. Gorman, Jill A. Hart, Patricia E. Noker, Yu‐Mei Tan, Paul H. Lieder, Christopher Lau, Geary W. Olsen, John L. Butenhoff	116
11	Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate 2007 ·Cancer Chemotherapy and Pharmacology ·Lee Jia, Lori Coward, (unknown), (unknown), Gregory S. Gorman, Patricia E. Noker, Shinichi Kitada, (unknown), John C. Reed	40
12	Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer 2007 ·American Journal of Obstetrics and Gynecology ·John G. Page, (unknown), Karen Schweikart, Joseph E. Tomaszewski, (unknown), (unknown), (unknown), Patricia E. Noker, Minghui Wang, Sharmila Makhija, (unknown), David T. Curiel, Ronald D. Alvarez	31
13	Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: Absence of toxicity due to saturating absorption 2007 ·Food and Chemical Toxicology ·Lee Jia, Karen Schweikart, Joseph E. Tomaszewski, John G. Page, Patricia E. Noker, Sarah A. Buhrow, Joel M. Reid, Matthew M. Ames, David H. Munn	79
14	Interspecies pharmacokinetics and in vitro metabolism of SQ109 2006 ·British Journal of Pharmacology ·Lee Jia, Patricia E. Noker, Lori Coward, Gregory S. Gorman, Marina Protopopova, Joseph E. Tomaszewski	76
15	Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (NSC19048). 2006 ·Blood ·Shinichi Kitada, Lee Jia, Lori Coward, Greg Gorman, Patricia E. Noker, Maurizio Pellecchia, John C. Reed	0
16	Pharmacoproteomic Effects of Isoniazid, Ethambutol, and N-Geranyl-N′-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Lee Jia, Lori Coward, Gregory S. Gorman, Patricia E. Noker, Joseph E. Tomaszewski	34
17	Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization 2004 ·Journal of Pharmaceutical and Biomedical Analysis ·Lee Jia, Joseph E. Tomaszewski, Patricia E. Noker, Gregory S. Gorman, (unknown), Marina Protopopova	27
18	Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug 2004 ·British Journal of Pharmacology ·Lee Jia, Joseph E. Tomaszewski, Colleen F. Hanrahan, Lori Coward, Patricia E. Noker, Gregory S. Gorman, B. V. Nikonenko, Marina Protopopova	184
19	Dose-Related Doxorubicin Effect in an Orthotopic Secondary Lung Cancer Screen 1994 ·Journal of Surgical Research ·Michael E. Cowen, Randy B. Howard, Patricia E. Noker, (unknown), D. Mulvin, (unknown), Michael R. Johnston	2
20	Secondary Screening System for Preclinical Testing of Human Lung Cancer Therapies 1992 ·JNCI Journal of the National Cancer Institute ·D. Mulvin, Randy B. Howard, Dawn H. Mitchell, Patricia E. Noker, Carol A. Kruse, (unknown), Paul A. Bunn, Michael R. Johnston	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact